Structures by: Pastorin G.
Total: 18
C13H19N5OS
C13H19N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=22.7776(4)Å b=6.85850(10)Å c=9.8800(2)Å
α=90° β=98.889(2)° γ=90°
C18H20ClCuN5OS,CH4O
C18H20ClCuN5OS,CH4O
Journal of medicinal chemistry (2019) 62, 2 512-530
a=16.5043(12)Å b=17.7857(12)Å c=7.1311(6)Å
α=90° β=96.241(3)° γ=90°
C14H21N5OS
C14H21N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=6.1236(4)Å b=7.9500(6)Å c=30.956(2)Å
α=90° β=92.419(4)° γ=90°
3(C16H22ClCuN5O2S),1.75(CH4O)
3(C16H22ClCuN5O2S),1.75(CH4O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=22.2413(7)Å b=8.3324(2)Å c=31.9121(9)Å
α=90° β=90.5654(13)° γ=90°
3(C16H22ClCuN5OS),0.75(CH4O)
3(C16H22ClCuN5OS),0.75(CH4O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=24.702(4)Å b=9.1959(14)Å c=25.064(5)Å
α=90° β=100.971(6)° γ=90°
C12H17N5OS
C12H17N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=11.544(3)Å b=13.204(3)Å c=10.086(3)Å
α=90° β=112.081(7)° γ=90°
C18H21N5OS
C18H21N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=7.1287(2)Å b=15.0536(6)Å c=16.4704(6)Å
α=90° β=97.810(2)° γ=90°
C16H23N5O2S
C16H23N5O2S
Journal of medicinal chemistry (2019) 62, 2 512-530
a=13.3622(18)Å b=5.8899(6)Å c=21.414(3)Å
α=90° β=91.631(5)° γ=90°
C13H18ClCuN5OS
C13H18ClCuN5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=15.7566(11)Å b=14.2967(9)Å c=14.2703(10)Å
α=90° β=92.971(3)° γ=90°
(C12H18ClCuN5O2S),2(H2O)
(C12H18ClCuN5O2S),2(H2O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=9.2626(8)Å b=9.5087(8)Å c=11.0617(9)Å
α=89.565(2)° β=76.519(2)° γ=67.742(2)°
C12H16ClCuN5OS,C3H7NO
C12H16ClCuN5OS,C3H7NO
Journal of medicinal chemistry (2019) 62, 2 512-530
a=9.3959(3)Å b=19.8889(6)Å c=10.9744(3)Å
α=90° β=108.3661(7)° γ=90°
(RuC29H32N2OCl)Cl2(CH3OH)
(RuC29H32N2OCl)Cl2(CH3OH)
Molecular pharmaceutics (2016) 13, 7 2543-2554
a=17.548(2)Å b=8.8135(12)Å c=20.148(3)Å
α=90° β=106.579(4)° γ=90°
(RuC28H29N2Cl2)Cl2(CH2Cl2)
(RuC28H29N2Cl2)Cl2(CH2Cl2)
Molecular pharmaceutics (2016) 13, 7 2543-2554
a=8.2070(3)Å b=12.9134(6)Å c=15.5705(7)Å
α=95.336(2)° β=104.273(2)° γ=96.960(2)°
C23H25ClF6N3OPRu
C23H25ClF6N3OPRu
Journal of medicinal chemistry (2014) 57, 14 6043-6059
a=9.887(2)Å b=18.473(4)Å c=14.002(3)Å
α=90.00° β=104.589(3)° γ=90.00°
4-Hydrazino-1-methylpyrazolo[3,4-<i>d</i>]pyrimidine
C6H8N6
Acta Crystallographica Section E (2009) 65, 8 o1720-o1721
a=14.086(4)Å b=3.8756(12)Å c=27.271(8)Å
α=90.00° β=90.00° γ=90.00°
<i>N</i>'-Acetyl-5-amino-1-methyl-1<i>H</i>-pyrazole-4-carbohydrazonamide dihydrate
C7H12N6O,2(H2O)
Acta Crystallographica Section E (2010) 66, 5 o1209-o1210
a=7.5496(9)Å b=7.6208(9)Å c=11.2518(13)Å
α=102.645(2)° β=101.440(2)° γ=110.810(2)°
(4<i>Z</i>,6<i>Z</i>,12<i>Z</i>,14<i>Z</i>)-2,10-Dimethyl-2,8,10,16- tetrahydrodipyrazolo[3,4-<i>e</i>:3',4'- <i>l</i>][1,2,4,8,9,11]hexaazacyclotetradecine-4,12-diamine
C12H16N12
Acta Crystallographica Section E (2009) 65, 7 o1578-o1579
a=7.1470(6)Å b=7.5593(7)Å c=13.9174(13)Å
α=90.00° β=91.866(3)° γ=90.00°
8-Methyl-2-[4-(trifluoromethyl)phenyl]-8<i>H</i>-pyrazolo[4,3-<i>e</i>][1,2,4]triazolo[1,5-<i>c</i>]pyrimidin-5-amine methanol disolvate
C14H10F3N7,2CH4O
Acta Crystallographica Section E (2010) 66, 7 o1835-o1836
a=4.6179(3)Å b=17.1149(10)Å c=22.7627(13)Å
α=90.00° β=94.3230(10)° γ=90.00°